Combining low-dose cyclophosphamide with GM-CSF–secreting prostate cancer immunotherapy enhances antitumor immune effects

Author： Antonarakis Emmanuel S   Carducci Michael A  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.19, Iss.2, 2010-02, pp. : 311-314

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Low-dose suramin improves QOL in prostate cancer

By  

Inpharma, Vol. 1, Iss. 1469, 2005-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Low-dose suramin improves QOL in prostate cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 468, 2004-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Increased Tumor Oxygenation and Drug Uptake During Anti-Angiogenic Weekly Low Dose Cyclophosphamide Enhances the Anti-Tumor Effect of Weekly Tirapazamine (Supplementry Material)

By  

Current Cancer Drug Targets, Vol. 9, Iss. 6, 2009-09 ,pp. : 777-788

Bentham Science Publishers

Access to resources Recommend Favorite

A Suicide Gene Therapy Combining the Improvement of Cyclophosphamide Tumor Cytotoxicity and the Development of an Anti-Tumor Immune Response

By  

Current Gene Therapy, Vol. 14, Iss. 3, 2014-06 ,pp. : 236-246

Bentham Science Publishers

Access to resources Recommend Favorite

Evaluation of the Adequacy of Published Studies of Low-Dose Effects of Bisphenol A on the Rodent Prostate for Use in Human Risk Assessment

By Milman H.A.   Bosland M.C.   Walden P.D.   Heinze J.E.  

Regulatory Toxicology and Pharmacology, Vol. 35, Iss. 3, 2002-06 ,pp. : 338-346

Academic Press

Access to resources Recommend Favorite